179 related articles for article (PubMed ID: 24606912)
1. Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients' prognosis.
Al Bashir S; Alshalalfa M; Hegazy SA; Dolph M; Donnelly B; Bismar TA
J Hematol Oncol; 2014 Mar; 7():21. PubMed ID: 24606912
[TBL] [Abstract][Full Text] [Related]
2. Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence.
Grupp K; Kohl S; Sirma H; Simon R; Steurer S; Becker A; Adam M; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
Mod Pathol; 2013 May; 26(5):733-42. PubMed ID: 23196798
[TBL] [Abstract][Full Text] [Related]
3. Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene.
Ribeiro FR; Paulo P; Costa VL; Barros-Silva JD; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
PLoS One; 2011; 6(7):e22317. PubMed ID: 21814574
[TBL] [Abstract][Full Text] [Related]
4. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
Bismar TA; Yoshimoto M; Vollmer RT; Duan Q; Firszt M; Corcos J; Squire JA
BJU Int; 2011 Feb; 107(3):477-85. PubMed ID: 20590547
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification.
Bismar TA; Hegazy S; Feng Z; Yu D; Donnelly B; Palanisamy N; Trock BJ
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2117-2125. PubMed ID: 30101374
[TBL] [Abstract][Full Text] [Related]
6. ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma.
Nagle RB; Algotar AM; Cortez CC; Smith K; Jones C; Sathyanarayana UG; Yun S; Riley J; Nagy D; Dittamore R; Dalkin B; Brosh L; Pestano G
Prostate; 2013 Aug; 73(11):1233-40. PubMed ID: 23653096
[TBL] [Abstract][Full Text] [Related]
7. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.
Huang KC; Evans A; Donnelly B; Bismar TA
Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancer.
Noh BJ; Sung JY; Kim YW; Chang SG; Park YK
Oncol Lett; 2016 Jun; 11(6):3621-3630. PubMed ID: 27284364
[TBL] [Abstract][Full Text] [Related]
9. ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer.
Huang KC; Dolph M; Donnelly B; Bismar TA
Clin Transl Oncol; 2014 Nov; 16(11):973-9. PubMed ID: 24796295
[TBL] [Abstract][Full Text] [Related]
10. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
11. Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome.
Bismar TA; Alshalalfa M; Petersen LF; Teng LH; Gerke T; Bakkar A; Al-Mami A; Liu S; Dolph M; Mucci LA; Alhajj R
BJU Int; 2014 Feb; 113(2):309-19. PubMed ID: 24006850
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.
Huang KC; Alshalalfa M; Hegazy SA; Dolph M; Donnelly B; Bismar TA
Cancer Biol Ther; 2014 Sep; 15(9):1120-8. PubMed ID: 24972028
[TBL] [Abstract][Full Text] [Related]
13. SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development.
Huang KC; Bégin LR; Palanisamy N; Donnelly B; Bismar TA
Urol Oncol; 2016 May; 34(5):235.e1-10. PubMed ID: 26725250
[TBL] [Abstract][Full Text] [Related]
14. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
Grupp K; Wilking J; Prien K; Hube-Magg C; Sirma H; Simon R; Steurer S; Budäus L; Haese A; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
Eur J Cancer; 2014 Mar; 50(4):852-61. PubMed ID: 24380696
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of ERG expression and PTEN loss in a Brazilian prostate cancer cohort.
Morais CE; Gurgel DC; Teixeira AC; Mattos TVA; Silva AVAD; Tavora F
Braz J Med Biol Res; 2019; 52(12):e8483. PubMed ID: 31826177
[TBL] [Abstract][Full Text] [Related]
16. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.
Leinonen KA; Saramäki OR; Furusato B; Kimura T; Takahashi H; Egawa S; Suzuki H; Keiger K; Ho Hahm S; Isaacs WB; Tolonen TT; Stenman UH; Tammela TL; Nykter M; Bova GS; Visakorpi T
Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2333-44. PubMed ID: 24083995
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.
Kim SH; Kim SH; Joung JY; Lee GK; Hong EK; Kang KM; Yu A; Nam BH; Chung J; Seo HK; Park WS; Lee KH
PLoS One; 2015; 10(4):e0122498. PubMed ID: 25897494
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T
BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication.
Abdelsalam RA; Khalifeh I; Box A; Kalantarian M; Ghosh S; Abou-Ouf H; Lotfi T; Shahait M; Palanisamy N; Bismar TA
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1701-1709. PubMed ID: 32350606
[TBL] [Abstract][Full Text] [Related]
20. Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers.
Burdelski C; Kleinhans S; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Tsourlakis MC; Wilczak W; Marx A; Sauter G; Wittmer C; Huland H; Simon R; Schlomm T; Steurer S
Int J Cancer; 2016 Mar; 138(5):1199-206. PubMed ID: 26383228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
